{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:46:35Z","timestamp":1760384795207,"version":"3.41.0"},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,4,10]],"date-time":"2008-04-10T00:00:00Z","timestamp":1207785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Relapsed\/refractory myeloma has a poor outcome because of multi\u2010drug resistance, patient low\u2010performance status and toxicity of conventional chemotherapy. To improve results, standard chemotherapeutics and drugs targeting the microenvironment are applied at the same time. Bortezomib, by inhibiting proteasome function, may enhance chemosensitivity to other drugs and overcome drug\u2010resistance. Notably, doxorubicin and bortezomib may reciprocally increase their efficacy. Thus, to improve outcome whilst minimizing therapy\u2010related toxicity, liposomal doxorubicin was added to a bortezomib\u2010based combination. From January 2004, relapsed\/refractory myeloma patients referred to our Institution received bortezomib 1\u00b70\u2003mg\/m<jats:sup>2<\/jats:sup> i.v. twice weekly for 2\u2003weeks in a 28\u2010d cycle for up to six cycles, oral dexamethasone 24\u2003mg with the standard scheduling and thalidomide 100\u2003mg continuously (VTD). From January 2005, liposomal doxorubicin, 50\u2003mg\/m<jats:sup>2<\/jats:sup> (30\u2003mg\/m<jats:sup>2<\/jats:sup> for patients older than 75\u2003years), was added on day 4 of each cycle [VTD plus Myocet (MyVTD)]. In total, 70 patients were treated: 28 received VTD and 42 MyVTD. Baseline demographic and clinical characteristics were similar between the two groups. Toxicity was manageable although more pronounced with MyVTD. The overall response rate (81% vs. 50%, <jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7009), time to progression (19 vs. 11\u2003months, <jats:italic>P<\/jats:italic>\u2003=\u20030\u00b701) and progression\u2010free survival (15 vs. 8\u2003months, <jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7001) were significantly higher with MyVTD regimen, suggesting an improved quality of response.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2008.07147.x","type":"journal-article","created":{"date-parts":[[2008,4,10]],"date-time":"2008-04-10T18:24:52Z","timestamp":1207851892000},"page":"814-819","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma"],"prefix":"10.1111","volume":"141","author":[{"given":"Stefania","family":"Ciolli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Casini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Breschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Santini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Bosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,4,22]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.06.037"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046409"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500272721"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00024669-200504030-00006"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"e_1_2_5_9_1","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study","volume":"91","author":"Harousseau J.L.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_5_10_1","first-page":"3071","article-title":"The proteasome inhibitor PS\u2010341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima T.","year":"2001","journal-title":"Cancer Research"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.7-suppl_1-20"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl477"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.11.4079"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1768"},{"volume-title":"Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","year":"2003","author":"National Cancer Institute","key":"e_1_2_5_15_1"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2911"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5460"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.4.2.171"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200403"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.030"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cco.0000245320.34658.bd"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0902-4441.2005.t01-1-EJH2462.x"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.055806"},{"key":"e_1_2_5_26_1","first-page":"6316","article-title":"The proteasome as a target for cancer therapy","volume":"9","author":"Voorhees P.M.","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/10245330701214236"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.001"},{"key":"e_1_2_5_29_1","first-page":"830a","article-title":"VTD regimen comprising Velcade(V) + Thalidomide (T) and added DEX (D) for non\u2010responders to V+T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant","volume":"102","author":"Zangari M.","year":"2003","journal-title":"Blood"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2008.07147.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2008.07147.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T04:02:17Z","timestamp":1747972937000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2008.07147.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,22]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1111\/j.1365-2141.2008.07147.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07147.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2008,4,22]]},"assertion":[{"value":"2008-04-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}